AirSculpt Sees Core Stabilization, Targets $100M-Plus GLP-1 Opportunity
AirSculpt Technologies' CEO Yogi Jashnani told a Canaccord consumer conference that its core body-contouring business is stabilizing after several quarters of declines, and that the company is expanding services aimed at patients using GLP-1 weight-loss drugs.
Why it matters — AIRS watchers would care because the company is signaling a potential turnaround in its core business while also broadening into the growing GLP-1-related service market.